VIDEO: Relistor effective in achieving rescue-free laxation in opioid-induced constipation
Click Here to Manage Email Alerts
In this video exclusive, Gregory S. Sayuk, MD, MPH, discussed a presentation from the ACG Annual Scientific Meeting on the use of Relistor for patients with opioid-induced constipation with advanced illness.
Sayuk, associate professor of medicine and psychiatry and associate director of the fellowship training program in the division of gastroenterology at Washington University School of Medicine and gastroenterologist at the John Cochran Veterans Affairs Medical Center, both in St. Louis, and colleagues performed a polled post hoc analysis of three randomized controlled trials comparing Relistor (methylnaltrexone, Salix Pharmaceuticals) with placebo in more than 500 patients with opioid-induced constipation. Patients were stratified by baseline opioid equivalent dose into three groups: patients taking less than 80 mg per day, 80 to 150 mg per day or more than 150 mg per day.
Sayuk said the most common adverse events were abdominal pain and flatulence.
“We found patients with higher opioid doses were more likely to experience these adverse events,” Sayuk said. “Methylnaltrexone was significantly more effective than placebo in achieving rescue-free laxation at 4 hours and 24 hours, and this was regardless of the opioid equivalent dose.”
Collapse
Sayuk GS. Poster: P1186. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Read more about
Click Here to Manage Email Alerts